Individualized Treatments in Adults With Relapsed/Refractory Cancers

Description

A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.

Conditions

Refractory Cancer, Relapsed Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.

Individualized Treatments in Adults With Relapsed/Refractory Cancers

Individualized Treatments in Adults With Relapsed/Refractory Cancers

Condition
Refractory Cancer
Intervention / Treatment

-

Contacts and Locations

Miami

Florida International University, Miami, Florida, United States, 33199

Weston

Lerner College of Medicine, Cleveland Clinic Florida, Weston, Florida, United States, 33331

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants aged 18 years or older at the time of enrollment on this study of any gender, race, or ethnicity.
  • * Patients with suspected or confirmed diagnosis of recurrent or refractory cancer with no curative treatment options.
  • * Participants who have undergone at least two lines of previous therapy.
  • * Participants who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) or who have scheduled or recently had paracentesis or thoracentesis performed.
  • * Participants willing to have a blood draw or buccal swab done for the purposes of genetic testing.
  • * Participants willing to sign informed consent.
  • * Participants who do not have malignant tissue available and accessible.
  • * Participants for whom the amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling.
  • * Participants with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Case Comprehensive Cancer Center,

Jorge Manrique-Succar, MD, PRINCIPAL_INVESTIGATOR, Lerner College of Medicine, Cleveland Clinic Florida

Diana Azzam, PhD, PRINCIPAL_INVESTIGATOR, Robert Stempel College of Public Health and Social Work, Florida International University

Study Record Dates

2025-11-01